Three Fibrotic Conditions Treated with 5% Topical Imiquimod Cream as an Antifibrotic Agent
- Author:
Yeo Rye CHO
1
;
Ho Jin KIM
;
Jeong Wan SEO
;
Tae Hoon KIM
;
Ki Ho KIM
Author Information
1. Department of Dermatology, College of Medicine, Dong-A University, Busan, Korea. khkim@dau.ac.kr
- Publication Type:Case Report
- Keywords:
Fibrosis;
Imiquimod;
Myxedema;
Angiolymphoid hyperplasia with eosinophilia;
Discoid lupus erythematosus
- MeSH:
Acitretin;
Angiolymphoid Hyperplasia with Eosinophilia;
Cytokines;
Fibrosis;
Humans;
Hyperplasia;
Interferon-alpha;
Lupus Erythematosus, Discoid;
Myxedema;
Skin;
Tacrolimus;
Toll-Like Receptors
- From:Korean Journal of Dermatology
2019;57(5):265-269
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Imiquimod, a toll-like receptor agonist, is a topical immunomodulator that induces the production of several cytokines including interferon-alpha, which shows antifibrotic properties. We hypothesized that the antifibrotic effect of imiquimod would soften fibrotic skin lesions. Therefore, we applied topical imiquimod with topical tacrolimus or systemic acitretin in patients with refractory lesions of myxedema, angiolymphoid hyperplasia, and generalized discoid lupus erythematosus and confirmed improvement in fibrotic lesions in these patients. Thus, we conclude that use of imiquimod improves fibrotic skin lesions. This report describes our experience with the treatment of this condition along with a review of the related literature.
